These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 10319915)

  • 41. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism.
    Muñoz NM; Douglas I; Mayer D; Herrnreiter A; Zhu X; Leff AR
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1398-403. PubMed ID: 9105085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lipid mediators in oxygen-induced airway remodeling and hyperresponsiveness in newborn rats.
    Burghardt JS; Boros V; Biggs DF; Olson DM
    Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):837-42. PubMed ID: 8887572
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines.
    He W; Pelletier JP; Martel-Pelletier J; Laufer S; Di Battista JA
    J Rheumatol; 2002 Mar; 29(3):546-53. PubMed ID: 11908571
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Derivatives of 2-[[N-(Aminocarbonyl)-N-hydroxyamino]methyl]-1,4- benzodioxan as orally active 5-lipoxygenase inhibitors.
    Satoh Y; Powers C; Toledo LM; Kowalski TJ; Peters PA; Kimble EF
    J Med Chem; 1995 Jan; 38(1):68-75. PubMed ID: 7837242
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential effect of 5- and 15-lipoxygenase products on ischemically sensitive abdominal visceral afferents.
    Pan HL; Stahl GL; Longhurst JC
    Am J Physiol; 1995 Jul; 269(1 Pt 2):H96-105. PubMed ID: 7631880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase.
    Karg EM; Luderer S; Pergola C; Bühring U; Rossi A; Northoff H; Sautebin L; Troschütz R; Werz O
    J Med Chem; 2009 Jun; 52(11):3474-83. PubMed ID: 19492852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum protein binding displacement: theoretical analysis using a hypothetical radiopharmaceutical and experimental analysis with 123I-N-isopropyl-p-iodoamphetamine.
    Kawai K; Nishii R; Shikano N; Makino N; Kuga N; Yoshimoto M; Jinnouchi S; Nagamachi S; Tamura S; Takamura N
    Nucl Med Biol; 2009 Jan; 36(1):99-106. PubMed ID: 19181274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Selective effects of antileukotrienes on leukotriene and histamine release in human dispersed lung cells.
    Larsson L; Sydbom A; Dahlén SE
    Inflamm Res; 1999 Apr; 48 Suppl 1():S9-10. PubMed ID: 10350138
    [No Abstract]   [Full Text] [Related]  

  • 49. Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors.
    Rainsford KD; Ying C; Smith F
    Agents Actions; 1993; 39 Spec No():C186-8. PubMed ID: 8273563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773.
    Carter GW; Bell RL; Marsh K; Lanni C; Awni WM; Bouska J; Stewart AO; Hansen R; Dubé L; Brooks DW
    Ann N Y Acad Sci; 1994 Nov; 744():262-73. PubMed ID: 7825849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of a continuous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors.
    Breton J; Keller P; Chabot-Fletcher M; Hillegass L; DeWolf W; Griswold D
    Prostaglandins Leukot Essent Fatty Acids; 1993 Dec; 49(6):929-37. PubMed ID: 8140120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A method for the separation of leukocytes from whole blood by flotation on serum albumin.
    VALLEE BL; HUGHES WL; GIBSON JG
    Blood; 1947 Jul; (1):82-7. PubMed ID: 20266790
    [No Abstract]   [Full Text] [Related]  

  • 53. WY-50, 295 tromethamine: an orally active 5-lipoxygenase inhibitor with anti-allergic activity.
    Weichman BM; Berkenkopf JW; Chang JY; Heaslip RJ; Kreft AF; Lewis AJ; Musser JH; Grimes D
    Agents Actions Suppl; 1991; 34():201-9. PubMed ID: 1793064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
    Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB
    Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood.
    Carlson R; Kreft A; Hartman D; Tomchek L; Lock Y; Weichman B; Glaser K
    Prostaglandins Leukot Essent Fatty Acids; 1999 Jan; 60(1):31-41. PubMed ID: 10319915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D; Sturm RJ; Marinari LR; Carlson RP; Berkenkopf JW; Musser JH; Kreft AF; Weichman BM
    Eur J Pharmacol; 1993 May; 236(2):217-28. PubMed ID: 8391458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-leukotriene effects of WY-50,295 tromethamine in isolated guinea pig pulmonary tissues.
    Heaslip RJ; Grimes D; Berkenkopf JW; Ilsemann BA; Sickels BD; Weichman BM
    Eur J Pharmacol; 1993 Apr; 234(2-3):247-54. PubMed ID: 8482329
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.